ABSTRACT
Results
We associated AIH with a variant in the major histocompatibility complex region at rs2187668 (P = 1.5 × 10 -78 ). Analysis of this variant in the discovery cohort identified HLA-DRB1*03:01 (P = 5.3 × 10 -49 ) as a primary susceptibility genotype and HLA-DRB1*04:01 (P = 2.8 × 10 -18 ) as a secondary susceptibility genotype. We also associated AIH with variants of SH2B3 (rs3184504, 12q24; P = 7.7 × 10 -8 ) and CARD10 (rs6000782, 22q13.1; P = 3.0 × 10 -6 ). In addition, strong inflation of association signal was found with single-nucleotide polymorphisms associated with other immune-mediated diseases, including primary sclerosing cholangitis and primary biliary cirrhosis, but not with single-nucleotide polymorphisms associated with other genetic traits.
Conclusions
In a genome-wide association study, we associated AIH type 1 with variants in the major histocompatibility complex region, and identified variants of SH2B3 and CARD10 as likely risk factors. These findings support a complex genetic basis for AIH pathogenesis and indicate that part of the genetic susceptibility overlaps with that for other immunemediated liver diseases.
INTRODUCTION
Autoimmune hepatitis (AIH) is an uncommon autoimmune liver disease of unknown aetiology. [1] [2] [3] The disease has a prevalence of approximately 17 per 100,000 and is characterised by chronic destructive inflammation within the liver parenchyma, elevated serum immunoglobulin G (IgG) levels and the presence of serum autoantibodies. [1] [2] [3] [4] AIH type-1 is associated with antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and soluble liver antigen/liver pancreas antibodies (SLA/LP) and occurs predominantly in adult women whereas the rare AIH type-2 occurs predominantly in children and is associated with liver kidney microsomal-1 antibodies (LKM-1). 1, 2 In up to 10% of patients a clinical overlap is seen with primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC). 5, 6 The manifestations of these respective traits in a subgroup of AIH patients may in fact be indicative that AIH is part of a spectrum of autoimmune liver diseases with shared genetic risk factors. 5, 6 Indeed, recent genome-wide association studies (GWAS) in PBC and PSC have identified several genetic risk factors underlying these traits. [7] [8] [9] [10] [11] [12] [13] [14] So far, there
have not been such genome-wide approaches in AIH. The only described and confirmed genetic association with AIH relates to human leukocyte antigen (HLA) class-II genotypes that have been distilled from candidate gene approaches in small study populations. 3, [15] [16] [17] [18] [19] No independent and reproducible associations outside the MHC have been identified. [20] [21] [22] [23] [24] [25] [26] [27] [28] Since genome-wide association studies (GWASs) have emerged as a powerful and unbiased approach for the identification of new genetic susceptibility loci in autoimmune diseases, 29 we applied this methodology in a large cohort of AIH patients and controls and replicated the identified loci in an independent set of patients and controls.
PATIENTS AND METHODS
The cases for the discovery set were identified by the Dutch AIH Studygroup consortium (http://www.autoimmuunhepatitis.nl), involving the gastroenterology and hepatology departments from 8 academic and 23 general hospitals in the Netherlands. AIH patients were identified by treating physicians and by searching the database for international classification of diseases (ICD) codes. The search was performed in local diagnostic registers in the departments of gastroenterology and hepatology as well as internal medicine. In all patients available clinical and biochemical parameters were assessed to characterize the patients and exclude other aetiologies such as alcohol, drugs and metabolic disorders. Viral hepatitis was excluded by serological testing. If performed, liver biopsy was used to establish diagnosis and the presence of fibrosis and cirrhosis. We recorded manifestations of overlap syndromes with PBC and PSC in the presence of AIH if these had been assessed. For PBC, these criteria consisted of anti-mitochondrial antibody (AMA) titres higher than 1:80 and typical histological findings, whereas manifestations of PSC were recorded in case of typical histological and radiological findings. The presence of other concomitant autoimmune disorders, including type-1 diabetes mellitus (T1DM), celiac disease (CeD), Hashimoto's disease, Sjögren syndrome (SS), colitis ulcerosa (CU) and Crohns disease (CD), was separately ascertained if noted in the medical records. Diagnostic scores were determined according to the revised original International Autoimmune Hepatitis Group (IAIHG) criteria. 4 Between 2008 and 2012, we recruited 743 patients with a clinical diagnosis of AIH in the discovery set. Twentyfour AIH patients (3%) with positive LKM-1 antibodies (AIH type-2) were excluded. After quality control (See Genotyping and quality control section) a total of 649 AIH type-1 cases were available for analysis. All 15,638 control subjects for the discovery set were included from LifeLines, a large population based cohort study conducted in the northern part of the Netherlands. 30 The replication cohort consisted of 466 patients with a clinical AIH diagnosis that had been identified and included in six centers in Germany and one center in Switzerland. After exclusion of patients with positive LKM-1 antibodies (AIH type-2), 451 cases were available for the replication analysis. The 4,103 controls for the replication cohort were drawn from the German population-based Study of Health in Pomerania (SHIP) which had previously been genotyped at the University Medicine Greifswald using the genome-wide Human Affymetrix SNP 6.0 platform. 31 Prior to the start of the study, institutional review board approval to carry out the study was obtained in all participating centers. All participants provided written informed consent.
GENOTYPING AND QUALITY CONTROL
Genotyping of all cases and controls in the Dutch set (discovery) was performed on the Illumina CytoSNP 12.0 platform (containing 300,739 SNPs) at the University Medical Center Groningen, the Netherlands. Twenty-three AIH cases with a call rate of less than 99% were excluded. We used multidimensional scaling (MDS) analysis to identify population ancestry and exclude ethnic outliers (n=34) as well as duplicates and relatives (n=3) among AIH cases study population. 32 We performed a sex check and excluded 10 AIH samples in which recorded sex did not correspond to the genotype-inferred sex. A total of 15,638 samples of LifeLines control subjects had previously been genotyped and subjected to quality control criteria. Of these, 2,202 samples did not pass quality control due to call rates less than 95% (n=129), ethnic outliers (n=486), duplicates and relatives (n=1,372) and samples in which recorded sex did not correspond to the genotype-inferred sex (n=215 
STATISTICAL ANALYSIS
Primary allelic association analysis was performed with PLINK v1.07 software package (http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml). We ascertained whether genomic inflation (λ > 1.0), indicative of false positive association results, was present as a result of population stratification between cases and controls. Principal component analysis (PCA) with EIGENSTRAT (http://genepath.med.harvard.edu/~reich/Software.htm) was applied to generate principal components which were used as covariates in the logistic regression analysis to control for this population stratification (Supplementary Figure 1) . 33 To further prevent false positive association results, we applied genomic control using the remaining inflation factor to generate adjusted P-values. 34 A P-value of <5.0 x 10 -8 was considered genome-wide significant. Manhattan and quantile-quantile plots were generated using the R software package (http://www.r-project.org/). In the replication cohort we performed chi-square analysis on the allelic frequencies of the selected SNPs in cases and controls to test for association using the R software package. A P-value of <0.05 after HolmBonferroni correction for multiple testing (P Holm-corr ) was considered statistically significant for replication. 35 Meta-analysis of discovery and replication results was performed with a P-value based, weighted method using METAL (http://www.sph.umich.edu/csg/abecasis/ Metal/). 36 Proportional weights of the discovery and replication panels were adjusted for the unequal size of cases and controls using the formula N eff = 4/(1/N cases + 1/N ctrls ). We used Cochran's Q-test to determine heterogeneity between discovery and replication results.
Autoimmune hepatitis associated markers were tested for association with clinical traits in the Dutch AIH samples with available data using linear or logistic regression analysis. A Pvalue of <0.05 was considered statistically significant. We subsequently assessed whether SNPs, previously found associated with autoimmune or immune-related disorders, showed a trend of association in the AIH discovery cohort. Metabolic disorder associated SNPs were selected as a reference for comparison. We selected established (auto)immune (n = 344) and other (metabolic) (n = 603) associated SNPs or representative markers (linkage disequilibrium r 2 : ≥ 0.8) that were available in our cohort from the GWAS catalog (http:// www.genome.gov/admin/gwascatalog.txt) (Supplementary Table 1 ). Inflation of signal factors (λ) for both the (auto)immune and other (metabolic) associated markers were calculated. 34 To correct for potential overestimation of effect due to known HLA involvement in (auto)immunity, this analysis was repeated after exclusion of markers that map in MHC region (chromosome 6: 20-40mb). The risk alleles of (auto)immune associated SNPs with P < 5.0 x 10 -3 were compared with the risk alleles for AIH . Probability for similar risk alleles was estimated using an exact binomial test. A P-value of <0.05 was considered statistically significant.
MHC imputation
Imputation of the HLA-genotype and amino acid polymorphism frequencies in the GWAS set was performed with the SNP2HLA imputation tool (http://www.broadinstitute.org/mpg/snp2hla/) on SNPs in the MHC region (20-40mb on chromosome 6). The 5,225 individuals of the Type 1 Diabetes Genetic Consortium (T1DGC) were used as a reference panel. 37 The mean estimated r 2 value of all 8,961 predicted markers with true genotypes was 0.98 (SD: 0.08).
RESULTS

Genome-wide association data and replication results
The initial discovery cohort consisted of 743 Dutch adult AIH patients and 15,638 Dutch control subjects. Twenty-four AIH cases (3%) had positive LKM-1 antibodies and were excluded. Figure 1) . 33 We used the first 10 principal components in the logistic regression analysis, which resulted in a reduction of genomic inflation (λ gc = 1.10). We then generated adjusted P-values with genomic control to further reduce the possibility of false-positive associations. 34 A Table 2) . 38 Nine independent loci (LD r 2 < 0.1) outside the MHC region were marked by individual SNPs with P-values at or below 5.0 x 10 -5 (Supplementary Table 2 ) and rs6000782 at 22q13.1 (OR 1.7, P GWAS = 1.8 x 10 ), rs3184504 (OR 1.2, P Holm-corr = 0.08) and rs6000782 (OR 1.4, P Holm-corr = 0.09) after correction for multiple testing (Table 2) . Weighted meta-analysis of the discovery and replication association results revealed a consistent outcome at rs2187668 (P GWAS+Repl = 1.5 x 10 -78 ), rs3184504 (P GWAS+Repl = 7.7 x 10 -8
) and rs6000782 (P GWAS+Repl = 3.0 x 10 -6 ) with similar direction and extent of effect (Table 2) . e Risk allele frequencies were assessed by Taqman® (cases) and Human Affymetrix 6.0 platform (controls) f Adjusted P-value using to Holm-Bonferroni correction (α = 0.05) g Weighted P-value based meta-analysis of discovery and replication results using METAL. h P-value for heterogeneity
Inflation of autoimmune and immune associated loci
The sample size and correction for population stratification in this study limited the statistical power to reach genome-wide significance for other loci that displayed a deviation from the expected frequencies. We next assessed if SNPs, previously associated with other autoimmune or immune-related disorders (Supplementary Table 1 ), showed a trend of association in our AIH GWAS. We indeed observed strong deviation from the expected P-values for autoimmune and immune-related SNPs associated with other immunemediated diseases (λ AI = 1.60) whereas no such deviation was seen for SNPs associated with metabolic disorders (λ MB = 1.08; Supplementary figure 3) which were selected as a reference. After exclusion of SNPs from the MHC region (chromosome 6, 20-40mb) we observed a similar inflation of the signal (λ AI = 1.46 versus λ MB = 1.05; Figure 2 ; Supplementary figure 3 ). Inspection of all SNPs with P < 5.0 x 10 -3 revealed that 9 of the 10 top SNPs have similar risk alleles (binomial test: P ≥10/11 = 5.9 x 10 -3
) to those reported for the immune related traits (Supplementary Table 4 ). To specifically compare genetic association results of AIH with PBC and PSC, available PBC (n=12) and PSC (n=8) risk loci in the non-overlap AIH GWAS were selected (Table 3) . Subsequent calculation of inflation factors revealed a marked inflation of AIH type-1 statistics for both PBC (λ PBC = 3.1) and PSC (λ PSC = 3.2). 
MHC imputation in AIH GWAS
To ascertain which specific HLA genotypes determine the association with AIH, we imputed classical HLA genotypes and amino acid polymorphisms in the Dutch AIH cases and controls. 37 
Clinical trait analysis
To establish the functional implications of the HLA-DRB1*0301, HLA-DRB1*0401 genotypes as well as the rs3184504*A and rs6000782*C alleles, we performed regression analyses on the following quantitative disease parameters in the cases of the discovery cohort: serum alanine aminotransferase (ALT) and IgG levels at presentation, age of onset and the presence of one or more concomitant autoimmune diseases other than PSC or PBC (Supplementary Table 5 ). HLA-DRB1*0301 was associated with earlier age of onset (β: -3.1 years, P = 4.0 x 10 -3 ) and higher IgG levels (β: 2.1 g/L, P = 5.9 x 10 -3 )
at presentation, but was not associated with baseline ALT levels (β: 24 U/L, P = 0.6) or concomitant autoimmune disease (OR 1.3, P = 0.05). In contrast, HLA-DRB1*0401 was associated with later onset of disease (β: 5.6 years, P = 1.2 x 10 -4 ) and was not associated with IgG (β: -0.03 g/L, P = 0.9), ALT levels (β: 79 U/L, P = 0.2) or concomitant autoimmune disease (OR 1.1, P = 0.5). The presence of the rs3184504*A allele was associated with concomitant autoimmune disease (OR: 1.3, P = 0.04) but not with age of onset, serum IgG, and ALT levels. The presence of the rs6000782*C allele was not associated with any of the investigated clinical traits.
DISCUSSION
The low prevalence (17 per 100,000) and heterogeneous presentation of AIH have precluded large-scale genetic studies so far in AIH. 1 Here, we studied a substantial discovery cohort and replication cohort of patients from the Netherlands and Germany/Switzerland, respectively. Despite the relatively small sample size we were able to identify several loci that are associated with the susceptibility to develop AIH type-1 and thus define AIH type-1 as a complex genetic disorder. The most prominent association was found with the HLA-DRB1*0301 and HLA-DRB1*0401 genotypes and these findings confirm and establish previous reports in small groups of Caucasian patients. 3, [15] [16] [17] [18] [19] These observa-tions further define the role of HLA in AIH disease pathogenesis using a hypothesis-free approach and show that this region confers the strongest genetic risk to AIH. Major histocompatibility complex class II molecules are expressed on professional antigen presenting cells (APCs) and primarily present exogenous antigens to CD4 positive T cells. Molecular mimicry, in which exogenous antigens trigger an immune response which is also directed at similar but endogenous antigens, has been proposed as a potential pathological mechanism in autoimmune disease development. 3 Some of these potential triggers may only be effectively presented by specific HLA class II molecules. 3 HLA-DRB1*0301 and HLA-DRB1*0401 share the 71K amino acid polymorphism, constituting the LLEQKR amino acid sequence at positions 67-72 which therefore may be the responsible AIH specific epitope binding sequence. 16, 19 Although both genotypes increase overall AIH susceptibility risk, we also show a contrast in relation to clinical characteristics. Thus, whereas HLA-DRB1*0301 is strongly associated with higher serum levels of the adaptive immune-system serum marker IgG, earlier age of onset and the presence of one or more concomitant autoimmune diseases, the HLA-DRB1*0401 genotype is associated with lower serum IgG levels and later age of onset and does not show associations with the presence of concomitant autoimmune diseases. In addition to the MHC locus, we identified an association with the rs3184504*A allele in the SH2B3 gene. It should be noted that this SNP did not exceed the stringent threshold for genome-wide significance, but it yielded a consistent result in both the discovery and replication analysis and most likely represents a true positive association. This SNP then represents the first genetic AIH locus outside the MHC. It encodes a missense variant in exon 3 of the Scr homology 2 adaptor protein 3 (SH2B3) gene located in the 12q24 region. SH2B3 is a negative regulator of T cell activation, tumor necrosis factor (TNF) and Janus kinase 2 and 3 (JAK2/3) signalling and plays an essential role in normal hemapotoesis. 39, 40 The AIH risk allele rs3184504*A results in replacement of the basic polar arginine with the nonpolar tryptophan at position 262 (R262W) in the pleckstrin homology domain of the SH2B3 protein. Recently expression quantitative trait locus (eQTL) analyses in 5,311 healthy individuals established that the AIH risk allele rs3184504*A is associated with higher expression levels of several genes involved in interferon-γ production, suggesting that the risk allele leads to an increased adaptive immune response whereas the protective rs3184504*C allele is associated with higher expression of genes involved in toll-like receptor (TLR) signalling. 41 The associated risk of the rs3184504*A allele for concomitant autoimmune diseases in this study is consistent with previous studies that identified this allele as a risk factor in PSC, PBC, type 1 diabetes mellitus (T1DM), hypothyroidism, rheumatoid arthritis and celiac disease (CeD). [42] [43] [44] [45] [46] The primary associations at HLA-DRB1*0301, HLA-DRB1*0401 and SH2B3 thus indicate a genetic overlap of AIH with other complex immune mediated diseases. The marked inflation of autoimmune and immune associated SNPs, specifically with PBC and PSC, found in this study further supports involvement of pleiotropic loci in AIH and other autoimmune (liver) diseases. 7 The suggestive association of rs6000782 with AIH indicates possible involvement of the caspase recruitment domain family member 10 (CARD10) gene which is positioned 12,643 base pairs downstream in the 22q13.1 region. CARD10 (or CARMA3) is a scaffold protein in the CARMA/Bcl10/MALT1 pathway, which induces proinflammatory NFkB activation and is widely expressed in a wide variety of non-hematopoetic tissues including hepatocytes.
47 CARD10 is activated through stimulation of G protein-coupled receptors (GPCRs) by angiotensin-II (Ang II) and lysophosphatidic acid (LPA), which in turn have been shown to induce the expression of proinflammatory and fibrogenic cytokines as well as extracellular matrix proteins in hepatic cell culture and animal models. [47] [48] [49] Also, CARD10 is overexpressed in several types of cancer and CARD10 deficiency has been shown to affect cancer cell proliferation, survival, migration and invasion. [50] [51] [52] [53] [54] The suggestive association in AIH reported here, is the first described association in an immune related trait and may therefore indicate specific involvement of CARD10 in AIH.
Despite the small size of the Netherlands, we observed substantial heterogeneity between the Dutch AIH cases, which were collected nationwide, versus the controls, which were mainly collected in the northern part of the Netherlands. As a consequence, the relatively small sample size for GWAS and correction for this population stratification limited the statistical power to identify disease susceptibility loci. Direct testing for association with loci that have been identified for other immune-mediated diseases nevertheless revealed strong inflation of signal, which indicates that these loci are most likely also involved in the susceptibility to AIH. In this study, selected SNP genotypes of cases and controls in the replication cohort were ascertained with different assessment methods (Taqman® assays vs Human Affymetrix 6.0). Although both methods are standardized and genotype clusters were checked manually, different clustering that in theory may have affected the outcome cannot be ruled out completely. Further studies in larger AIH cohorts and denser genotyping techniques are mandatory to improve statistical power, whereas meta-analyses and combination analyses with clinically and genetically overlapping autoimmune traits will likely result in the identification of more AIH susceptibility loci. 46, [55] [56] [57] In summary, we have performed the first genome-wide association study in AIH and unequivocally established AIH type-1 as complex genetic disorder with strong involvement of the MHC region. We were able to refine the MHC association to amino acid lysine 71 in the HLA-DR beta chain and identified SH2B3 as the first non-HLA genetic risk factor for AIH. Our findings support that part of the genetic susceptibility for AIH type-1 overlaps with other immune-mediated diseases, including PBC and PSC. in the AIH GWAS (discovery set). Green marks SNPs with common risk alleles between AIH and the mentioned autoimmune and immune-related traits, whereas yellow marks the opposite allele.
